Immunovant Inc (NAS:IMVT)
$ 26 -0.6 (-2.26%) Market Cap: 3.80 Bil Enterprise Value: 3.16 Bil PE Ratio: 0 PB Ratio: 6.13 GF Score: 42/100

Immunovant Inc Fireside Chat Hosted by LifeSci Capital Transcript

Dec 08, 2022 / 03:00PM GMT
Release Date Price: $14.97 (+2.39%)
Samuel Evan Slutsky
LifeSci Capital, LLC, Research Division - Senior Research Analyst

We're joined today by Dr. Peter Salzmann, the company's CEO. And in terms of format, there will be a presentation on the background and positioning of Immunovant FcRn inhibitors and then this will be followed up for some Q&A. And with that, over to you, Pete. Thanks, Sam.

Peter Salzmann
Immunovant, Inc. - CEO & Director

And I appreciate the invitation to be a good amount of material. So I'm going to, as you mentioned, go through that material, then we'll have plenty of time for Q&A. We'll be making some forward-looking statements today, and I direct investors to carefully read this statement, which is part of the 8-K where we released this slide deck this morning. Just for a quick orientation. These are the programs that we have in development across our 2 assets, pitolimab and 1402 today, post education on a lot of preclinical biology related to 1402. And then also, you talk about chronic inflammatory demyelinating polyneuropathy or CIDP in our program there.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot